Royal Bank of Canada reiterated their outperform rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has a $16.00 target price on the stock.
Separately, HC Wainwright reissued a buy rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Thursday, August 1st.
Read Our Latest Research Report on ATYR
Atyr PHARMA Trading Down 4.5 %
Atyr PHARMA (NASDAQ:ATYR – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. Research analysts anticipate that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.
Insider Buying and Selling at Atyr PHARMA
In related news, Director Paul Schimmel acquired 52,300 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The stock was bought at an average price of $1.93 per share, for a total transaction of $100,939.00. Following the acquisition, the director now directly owns 413,023 shares of the company’s stock, valued at $797,134.39. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.70% of the company’s stock.
About Atyr PHARMA
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Read More
- Five stocks we like better than Atyr PHARMA
- Options Trading – Understanding Strike Price
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 8/12 – 8/16
- Do ETFs Pay Dividends? What You Need to Know
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.